Introduction
The standard treatment for vaginal trichomoniasis during the past 10 years has been oral metronidazole (Flagyl) ; this drug is a substituted nitroimidazole, (1-(2-Hydroxyethyl)-2 methyl-5-nitroimidazole) (see formula). Clinical trials on the Continent have claimed a success rate of 96% following oral use of this drug (Emanueli and de Carneri, 1969) ; gastrointestinal side effects were noted in 7% of cases.
The results of two uncontrolled cinial trials have recently been published in Britain. Both report cure rates of over 90% and no side effects (Cohen, 1971; Moffett et al., 1971 amination, leaving 57 patients who were re-examined. Cure was established in 51 (890% ) on the minimum basis of a single examination (Table I) ; one patient had persistent trichomonal infestation at the first examination and five were infested at their second follow-up test (Table II) . One patient in each group reported anorexia and nausea while under treatment; there were no other adverse effects. No evidence of depression of leucocyte production was found with either drug.
Gonorrhoea, confirmed by culture and fermentation tests, was found before treatment in 10 (14%) patients who received nitrimidazine and in 13 (180,/ ) treated with metronidazole.
A further case of gonorrhoea was found at the first posttreatment examination two weeks after beginning metronidazole. However, no more cases of gonorrhoea were diagnosed in a total of 211 sets of genital tests. Gonorrhoea recurred in two patients in both groups.
Candida albicans was isolated on the initial examination in 12 (17%o) patients who received nitrimidazine and in 13 (180/,) given metronidazole. Treatment with nystatin pessaries was given only to those patients who had unequivocal candidiasis on Gram-stained vaginal material in all cases, subsequently confirmed by culture on Sabouraud's medium. One patient was completely refractory to treatment and firmly maintained that she had never had sexual intercourse. After initial failure with metronidazole, which made her nauseated, she failed successively to show any response to nitrimidazine, hydrargaphen pessaries, and chloramphenicol pessaries. Metronidazole given at the clinic as a single 4-g dose together with 800 mg into the vagina did not eradicate the organism. Further investigation carried out in conjunction with the manufacturer showed a serum metronidazole concentration of 2-3 jg/ml one hour after 200 mg by mouth; this is considered the minimum level consistent with adequate absorption (Kane et al., 1961) . The strain of T. vaginalis isolated was sensitive to the drug (minimal inhibitory concentration 1 [kg/ml), and there was no inactivation of metromonidazole after incubation with the patient's vaginal flora. Metronidazole (1-2 g daily) was then combined with chloramphenicol pessaries (Ginetris) one nightly for one week, but, despite temporary symptomatic improvement, the organism was still found three weeks later. She was then admitted to hospital where this regimen was repeated under supervision and produced a cure; metronidazole tablets were administered crushed in milk. It was concluded that this was a case of inconsistent consumption of the drug owing to gastrointestinal intolerance coupled with reduced absorption. Discussion Failure to respond to metronidazole seems to occur in less than 10 % of cases though it is never possible to exclude the patient's failure to have taken the drug as prescribed or to have avoided reinfection (Rodin et al., 1960; Watt and Jennison, 1962; Csonka, 1963; Wisdom and Dunlop, 1965) . The report by Keighley (1971) from a prison community is of particular relevance; she found a 98 % cure rate with metronidazole under conditions where medication was seen to be administered and reinfection by heterosexual intercourse was, presumably, not possible. Nevertheless, her cases received a larger daily dose (800 mg) than normally prescribed to fit in with the twice daily treatment routine in prison. Inadequate absorption and low serum levels probably account for some drug failures (Kane et al., 1961) . Neither primary nor acquired resistance has been reported after eight years of clinical use (McFadzean et al., 1969) . However, Nicol et al., (1966) Nevertheless, in the treatment of vaginal trichomoniasis metronidazole approaches the therapeutic ideal in ease of administration, freedom from unwanted effects, and high cure rate. Substances of similar chemical structure are being produced. The present one under trial claims the advantage of twice-daily administration for a course one day less than metronidazole; thus the daily dose of nitrimidazine recommended (500 mg) is less than that of metronidazole (600 mg). Clearly this will be invalidated by any loss of therapeutic efficiency such as is shown by the present figures in which nitrimidazine cured only 68% of patients whereas metronidazole cured 89%. The latter figure is in agreement with the results of previous trials (Wisdom and Dunlop, 1965; Evans and Catterall, 1970) .
